Editor of Patient Care Online.
Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure
Your daily dose of clinical news you may have missed.
Antiobesity Medications: Expert Discusses Older, Newer Therapies
Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.
Daily Dose: COVID-19 Vaccination Decreases Symptoms of Long COVID
Remote Bilingual Program Proves Effective in Controlling Blood Pressure in Underserved Population
New research presented at Hypertension 2023 showed a novel digital bilingual hypertension control program improved BP control rates by more than 30%.
Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years
Hypertension While Lying Down Linked to Elevated Risk for CVD Events
Persons with HTN while in a supine position had a higher risk for CVD even if they did not have HTN while seated, according to new research presented at Hypertension 2023.
Daily Dose: DAPT Should Remain Gold Standard for Percutaneous Coronary Intervention
Daily Dose: Osteoarthritis Estimated to Affect Nearly 1 Billion by 2050
SSRI Treatment May Decrease Risk for Postnatal Depression-Associated Outcomes for Mother, Child
Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.
Daily Dose: Semaglutide 2.4 mg Benefits Patients with Heart Failure and Obesity
COVID-19 Vaccination May Decrease Symptoms of Long COVID, Report Mayo Clinic Researchers
Vaccination against SARS-CoV-2 may decrease the symptoms of post-COVID conditions, such as abdominal pain and weakness, according to new study.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Daily Dose: Aspirin for Secondary Prevention of Cardiovascular Disease
Dual Antiplatelet Therapy Should Remain Gold Standard for Percutaneous Coronary Intervention, Say Authors of New Study
ESC 2023: New data showed an aspirin-free strategy after PCI did not reduce major bleeding event risk vs DAPT, while omission of aspirin proved noninferior for CV events in high-risk patients.
Daily Dose: FDA Approves First Biosimilar for Multiple Sclerosis
Dapagliflozin Did Not Meet Primary Endpoint in DICTATE-AHF Trial of Patients with Acute Decompensated Heart Failure
ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.
Daily Dose: Semaglutide May Benefit 93 Million US Adults
A daily dose of clinical news on Patient Care you may have missed.
New-Onset Inflammatory Rheumatic Diseases May be Triggered by SARS-CoV-2 Infection or COVID-19 Vaccines, According to Recent Data
Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.
Consider Age when Assessing Children for COVID-19 Severity, Advise Authors of New Study
A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
Aspirin Underused for Secondary Prevention of CVD Worldwide, Especially in Lower-Income Countries
In an analysis of participant data from health surveys, less than half of eligible persons in the overall pooled sample were taking aspirin for secondary prevention of CVD.
Daily Dose: Characteristics of RSV-Related Critical Illness in Infants during 2022 Peak
Obesity Management in Primary Care: Tailor Nutrition Plans to Individual Patient Needs
Before creating a nutrition plan for patients with obesity, clinicians should first understand their eating patterns, says one obesity expert.
FDA Approves First RSV Vaccine for Use in Pregnant Individuals to Prevent LRTD in Infants
The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
Daily Dose: Recreational Drug Use in Patients with Acute CV Events
Patients with COVID-19 More Likely to Develop Hypertension than Those with Influenza, Shows New Study
Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.
Daily Dose: AAP's 12 Tips to Prep Children for Back-to-School Season
US Infants Admitted to ICU in 2022 for RSV Mostly Young, Healthy, and Born at Term
Approximately 80% of infants hospitalized with an RSV-related illness during the 2022 seasonal peak did not have underlying medical conditions, according to new study.
Daily Dose: Role of Heavy Menstrual Bleeding in Iron Deficiency Anemia Overlooked
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women